Table 3:
Recommendations for reporting standards.
| Reporting recommendations | |
|---|---|
| Clinical | Up to 5 years of outcome, including local control, interlobar control, local regional control (hilar/mediastinal recurrences), rates of distant metastases, overall survival, histology, tumor molecular makeup, medical operability status, tumor location, tumor size, and treatment related toxicities |
| Treatment simulation | Type of images, treatment immobilization, motion management strategies (breath-hold, gating, tracking, ITV, etc.) |
| Target volume definitions | Definition of GTV, ITV, CTV (if added), PTV margins |
| Dose calculation | Dose calculation algorithm used, heterogeneity correction, prescription parameters (isocenter, % of PTV, or specific isodose line), minimal GTV, ITV, or PTV coverage, mean doses, maximum doses, and equivalent uniform dose. % of GTV receiving > 110% of prescribed dose, the GTV D95%, Total dose, dose per fraction, total number of fractions, number of elapsed days during treatment |
| Dose delivery | Dose delivery machine, type of image guidance (4D, 3D, 2D, gated), frequency of image guidance, motion management strategies (breath-hold, gating, tracking,compression), motion monitoring |